Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
1.56M
-
Number of holders
-
9
-
Total 13F shares, excl. options
-
242K
-
Shares change
-
+23.8K
-
Total reported value, excl. options
-
$666K
-
Value change
-
+$63.2K
-
Number of buys
-
3
-
Number of sells
-
-2
-
Price
-
$2.75
Significant Holders of Evoke Pharma Inc - Common Stock (EVOK) as of Q1 2025
10 filings reported holding EVOK - Evoke Pharma Inc - Common Stock as of Q1 2025.
Evoke Pharma Inc - Common Stock (EVOK) has 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 242K shares
of 1.56M outstanding shares and own 15.53% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (148K shares), Bleichroeder LP (68.8K shares), CITADEL ADVISORS LLC (24.8K shares), Tower Research Capital LLC (TRC) (213 shares), BlackRock, Inc. (122 shares), SBI Securities Co., Ltd. (75 shares), MORGAN STANLEY (64 shares), NewEdge Advisors, LLC (17 shares), BANK OF AMERICA CORP /DE/ (9 shares), and UBS Group AG (0 shares).
This table shows the top 9 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.